Blood biomarkers for appendicitis and diagnostics methods using biomarkers
AssigneeTrue Bearing Diagnostics, Inc.
InventorsLakhmir S. CHAWLA, Timothy A. McCAFFREY
Life of this patent
Estimating the term…
Abstract
The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising obtaining a biological sample rom said subject; detecting RNA expression levels of at least three or more biomarkers in the biological sample and comparing the expression levels of said at least three or more biomarkers to a control sample wherein an increase or decrease in the level of expression of said at least three or more biomarkers as compared to the control sample is indicative of appendicitis.
Claims21
A method of diagnosing appendicitis in a subject, comprising:
- obtaining a biological sample from said subject;
- detecting expression levels of at least three or more biomarkers in the biological sample selected from the group consisting of Chemokine C-X-C receptor 1, Interleukin 8 receptor B, Fe frag of IgG receptor IIIb (CD16b), MHC class TI DR beta 5, Leukocyte IgG-like receptor A3, Defensin alpha 1, Defensin alpha 1B, Defensin alpha 3, 18S ribosomal RNA, CDC14A, 28S ribosomal RNA, 60S acidic ribosomal protein P1, 40S ribosomal protein S26, Ribosomal protein L23, Ribosomal protein L37a, Ribosomal protein S28, Alkaline phosphatase, Carbonic anhydrase IV, Neuroblastoma breakpoint family 10, Ninjurin 1, Prok:ineticin 2, Superoxide dismutase 2, LOC100129902, LOC100131205, LOC100131905, LOC100132291, LOC100132394, LOC100132742, LOC100134364, LOC391370, LOC646785, LOC644191 and C5orf32;
- and
- comparing the expression levels of said at least three or more biomarkers to a control sample wherein an increase or decrease in the level of expression of said at least three or more biomarkers as compared to the control sample is indicative of appendicitis.
A method of treating appendicitis in a subject, comprising:
- obtaining a biological sample from said subject;
- detecting expression levels of at least three or more biomarkers in the biological sample selected from the group consisting of Chemokine C-X-C receptor 1, Interleukin 8 receptor B, Fe frag of IgG receptor IIIb (CD16b), MHC class TI, DR beta 5, Leukocyte IgG-like receptor A3, Defensin alpha 1, Defensin alpha 1B, Defensin alpha 3, 18S ribosomal R. A, CDC14A, 28S ribosomal RNA, 60S acidic ribosomal protein P1, 40S ribosomal protein S26, Ribosomal protein L23, Ribosomal protein L37a, Ribosomal protein S28, Alkaline phosphatase, Carbonic anhydrase IV, Neuroblastoma breakpoint family 10, Ninjurin 1, Prokineticin 2, Superoxide dismutase 2, LOC100129902, LOC100131205, LOC100131905, LOC100132291, LOC100132394, LOC100132742, LOC100134364, LOC391370, LOC646785, LOC644191 and C5orf32;
- I. comparing the expression levels of said at least three or more biomarkers to a control sample wherein an increase or decrease in the level of expression of said at least three or more biomarkers as compared to the control sample is indicative of appendicitis;
- and
- treating the subject for appendicitis.
21-32. (canceled)
Dependencies are inferred from the claim text.